17
Participants
Start Date
August 17, 2021
Primary Completion Date
August 22, 2022
Study Completion Date
August 22, 2022
BMS-986166
Specified dose on specified days
Branebrutinib
Specified dose on specified days
Placebo
Specified dose on specified days
Holdsworth House Medical Practice, Sydney
Westmead Hospital-Dermatology, Westmead
Premier Dermatology, Kogarah
Sinclair Dermatology, East Melbourne
Local Institution, Linz
Local Institution, New York
Charité Universitaetsmedizin Berlin - Campus Mitte, Berlin
Local Institution, Berlin
Local Institution - 0130, Córdoba
Local Institution - 0094, Pittsburgh
Local Institution - 0078, Philadelphia
Dermatology and Skin Cancer Specialists, LLC, Rockville
Universitatsklinikum Schleswig-Holstein, Kiel
Local Institution - 0003, Morgantown
Hospital Universitario La Paz-UCICEC/DERMA, Madrid
Local Institution, Hanover
Local Institution - 0006, Miami Lakes
Local Institution - 0110, Margate
Local Institution - 0061, Coral Gables
Local Institution - 0112, Brandon
Local Institution, Tampa
Hospital Universitario de Gran Canaria Doctor Negrín-Dermatología, Las
Local Institution - 0083, Louisville
Local Institution - 0034, Bochum
Local Institution - 0081, Indianapolis
KliFOs - Klinische Forschung Osnabrück, Osnabrück
Universitätsklinikum Bonn-Studienzentrum Dermatologie, Bonn
Private Practice - Dr. Ralph von Kiedrowski, Selters
Local Institution - 0008, Skokie
Local Institution - 0051, Saint Joseph
The University of Texas Health Science Center at Houston, Bellaire
Local Institution, San Antonio
Local Institution, Munich
Local Institution - 0091, Fremont
Local Institution, Markham
York Dermatology Clinic and Research Centre, Richmond Hill
SIMa Recherche, Verdun
SRH Wald-Klinikum Gera-Zentrum für klinische Studien, Gera
Royalderm Agnieszka Nawrocka, Warsaw
NZOZ Centrum Medyczne KERmed, Bydgoszcz
ETYKA Osrodek Badan Klinicznych, Olsztyn
Hospital General Universitario de Alicante-Dermatology, Alicante
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY